Science and Discovery

Lorlatinib

1 article

Microscopic view of lung cancer cells being targeted by Pfizer's lorlatinib, illustrating a breakthrough in targeted cancer therapy and improved patient survival rates.
Cosmos & Space

Pfizer lung cancer drug: 60% progression-free after five years

After five years, 60% of patients with a specific type of lung cancer treated with Pfizer's lorlatinib were still alive without their disease progressing, a dramatic finding compared to just 8% on the

Marcus Cole·June 23, 2026